T1	Lab_value_phrase 299 332	a massive (>5 cm) tumor of intra-
T2	Lab_value 311 315	5 cm
T3	Diagnostic_procedure 317 322	tumor
T4	Lab_value_phrase 456 654	Further testing revealed an exceedingly high-serum level of prolactin (PRL) (4408 ng/ml), whereas levels of all other pituitary hormones were within reference ranges (growth hormone (GH), 0.50 ng/ml
T5	Lab_value 533 543	4408 ng/ml
T6	Diagnostic_procedure 516 525	prolactin
T7	Lab_value_phrase 656 693	luteinizing hormone (LH), 2.60 mIU/ml
T8	Lab_value 682 693	2.60 mIU/ml
T9	Diagnostic_procedure 677 679	LH
T10	Lab_value_phrase 695 742	follicle-stimulating hormone (FSH), 4.57 mIU/ml
T11	Lab_value 731 742	4.57 mIU/ml
T12	Diagnostic_procedure 725 728	FSH
T13	Lab_value_phrase 744 790	adrenocorticotropic hormone (ACTH), 37.4 pg/ml
T14	Lab_value 780 790	37.4 pg/ml
T15	Diagnostic_procedure 773 777	ACTH
T16	Lab_value_phrase 792 840	thyroid-stimulating hormone (TSH), 2.68 μIU/ml).
T17	Lab_value 827 838	2.68 μIU/ml
T18	Diagnostic_procedure 821 824	TSH
T19	Lab_value_phrase 1084 1108	cabergoline (1 mg/week),
T20	Lab_value 1097 1106	1 mg/week
T21	Diagnostic_procedure 1084 1095	cabergoline
T22	Lab_value_phrase 1113 1160	serum PRL level (2207 ng/ml) remained elevated.
T23	Lab_value 1130 1140	2207 ng/ml
T24	Diagnostic_procedure 1119 1122	PRL
T25	Lab_value_phrase 1613 1687	serum PRL level declined (to 250 ng/ml) in steps at each procedural stage.
T26	Lab_value 1642 1651	250 ng/ml
T27	Diagnostic_procedure 1619 1622	PRL
T28	Lab_value_phrase 1688 1811	But the normalization of PRL level had not been achieved with the administration of cabergoline increased up to 0.5 mg/day.
T29	Lab_value 1800 1810	0.5 mg/day
T30	Diagnostic_procedure 1713 1716	PRL
